Some predicted that drugmakers might boost launch prices to make up for Medicare drug negotiations shrinking profits. Harvard researchers find no evidence of that happening so far.
|Slideshows|July 18, 2018
Seven Most Out-Of-Reach Drugs for Patients Due to High Costs
Author(s)Tracey Walker
Drug costs are increasing, but so is patient cost sharing. That’s raising serious problems for some patients. Here are seven of the most out-of-reach drugs due to high costs, according to industry watchers.
Advertisement
Drug costs are increasing, but so is patient cost sharing. That’s raising serious problems for some patients. Here are seven of the most out-of-reach drugs due to high costs, according to industry watchers.
Advertisement
Related to this article
Onswik is approved to improve glycemic control in adults with Type 2 diabetes and will be available in the United States in the coming months in two concentrations. No information is available on the list price.
UCLA research suggests that GLP-1 therapies may protect bone health in Type 2 diabetes patients.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Closing the outpatient monitoring gap in cancer
2
A conversation with Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, about the relationship between HIV incidence in Hispanic communities and immigration policy
3
A conversation with Eric Seiber, Ph.D., about why defining first-episode psychosis matters
4
Final GLOBE drug model projects much smaller savings while 2027 Part D premiums split
5